Blog Viewer

Trial of Dexamethasone for Chronic Subdural Hematoma

By Currents Editor posted 01-19-2021 13:42

  

New England Journal of Medicine (12/31/21) doi: 10.1056/NEJMoa2020473

Hutchinson, Peter J.; Edlmann, Ellie; Bulters, Diederik; et al.

https://www.nejm.org/doi/full/10.1056/NEJMoa2020473

 

Patients with chronic subdural hematoma who were treated with dexamethasone had fewer favorable outcomes and more adverse events at six months compared with those who received placebo, according to new research. The multicenter, randomized trial — which was conducted in the United Kingdom from August 2015 through November 2019 — included 748 adults with symptomatic chronic subdural hematoma. The participants had a mean age of 74 years, and 94% had undergone surgery to remove their hematomas during the index admission. In each group, 60% of the patients had a score of 1 to 3 on the modified Rankin Scale at admission. A modified intention-to-treat analysis involving 680 patients showed a favorable outcome — a score of 0 to 3 on the modified Rankin Scale at six months after randomization — in 83.9% patients (286 of 341) in the dexamethasone group and in 90.3% (306 of 339) of the placebo group. In all, 1.7% (6) patients in the dexamethasone group and 7.1% (25) in the placebo group had repeat surgery for recurrence for the hematoma. Adverse events were more frequent in the dexamethasone group compared with the placebo group, with serious adverse events occurring in 16.0% and 6.4%, respectively. Adverse events of special interest — including hyperglycemia leading to treatment or discontinuation of the trial regimen, new-onset diabetes, hyperosmolar hyperglycemic state, new-onset psychosis, and upper gastrointestinal adverse effects — were reported in 10.9% and 3.2% in the two groups, respectively. The risk of any infection was 6.4% in the dexamethasone arm vs. 1.1% in the placebo arm.

#LiteratureWatch

​​
FURTHER READING
Shweta Goswami, MD, University of Florida Sasha Yakhkind, MD, University of Pennsylvania Every year, neurology residents combine the wisdom of their mentors, their experience, their passion, and their personalities to guide them in the decision of sub-specialization. In 2017, 90% of neurology residents ...
Luis Rafael Moscote-Salazar, MD Critical Care Unit, Bogotá, Colombia Centro Policlínico del Olaya I ván David Lozada-Martínez, MS University of Cartagena Cartagena, Colombia View Blog in English Las enfermedades neurológicas y neuroquirúrgicas son una de las principales causas ...
Luis Rafael Moscote-Salazar, MD Critical Care Unit, Bogotá, Colombia Centro Policlínico del Olaya I ván David Lozada-Martínez, MS University of Cartagena Cartagena, Colombia Blog en Español Neurological and neurosurgical diseases are a major cause of morbidity and mortality worldwide, ...